Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279288 | 0.67 | EGFR (0.34) | EGFR | |
| SCHEMBL2361668 | 0.63 | EGFR (0.44) | EGFR | |
| SCHEMBL6235782 | 0.63 | — | — | |
| SCHEMBL11510129 | 0.61 | — | — | |
| SCHEMBL6805575 | 0.60 | — | — | |
| SCHEMBL2879037 | 0.59 | EGFR (0.48) | EGFR | |
| SCHEMBL9345261 | 0.58 | — | — | |
| SCHEMBL4751006 | 0.58 | — | — | |
| SCHEMBL3654997 | 0.58 | — | — | |
| SCHEMBL29809882 | 0.57 | EGFR (0.46) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043067-A3 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE | CARDURION PHARMACEUTICALS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12251372-B2 | Antileishmanial compounds, compositions and use thereof | TRUSTEES OF BOSTON UNIVERSITY | 2025-03-18 | — | — | US | disclosed |
| WO-2025043067-A2 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE | CARDURION PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240279234-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | UTI LIMITED PARTNERSHIP (CA) | 2024-08-22 | — | — | US | disclosed |
| US-11999737-B2 | Kinase inhibitors and related methods of use | DUKE UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023230217-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | disclosed |
| US-20210155627-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | UTI LIMITED PARTNERSHIP (CA) | 2021-05-27 | — | — | US | disclosed |
| US-10934291-B2 | Kinase inhibitors and related methods of use | DUKE UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6028074-A | FOR TREATING ALLOGRAFT REJECTION | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-02-22 | — | — | US | disclosed |
| EP-0496617-B1 | Adenosine kinase inhibitors | METABASIS THERAPEUTICS INC (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0682519-A4 | ADENOSINE KINASE INHIBITORS. | GENSIA INC (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0682519-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994017803-A9 | ADENOSINE KINASE INHIBITORS | — | 1994-09-29 | — | — | WO | disclosed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279234-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | DAPK2, DAPK1, DAPK3 | EGFR 564/4885 |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | MPO, SSB, SGMS2 | EGFR 4821/4885 |
| US-10934291-B2 | Kinase inhibitors and related methods of use | DAPK2, DAPK1, DAPK3 | EGFR 564/4885 |
| US-11999737-B2 | Kinase inhibitors and related methods of use | DAPK2, DAPK1, DAPK3 | EGFR 564/4885 |
| US-20210155627-A1 | KINASE INHIBITORS AND RELATED METHODS OF USE | DAPK2, DAPK1, DAPK3 | EGFR 564/4885 |
| US-12251372-B2 | Antileishmanial compounds, compositions and use thereof | MPO, SSB, SGMS2 | EGFR 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.